JP2018537665A - 薬物アレルギー反応の起因薬物を同定するための方法及びキット - Google Patents
薬物アレルギー反応の起因薬物を同定するための方法及びキット Download PDFInfo
- Publication number
- JP2018537665A JP2018537665A JP2018522116A JP2018522116A JP2018537665A JP 2018537665 A JP2018537665 A JP 2018537665A JP 2018522116 A JP2018522116 A JP 2018522116A JP 2018522116 A JP2018522116 A JP 2018522116A JP 2018537665 A JP2018537665 A JP 2018537665A
- Authority
- JP
- Japan
- Prior art keywords
- drug
- granulysin
- expression level
- identifying
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 152
- 229940079593 drug Drugs 0.000 title claims abstract description 146
- 238000000034 method Methods 0.000 title claims abstract description 44
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 35
- 208000030961 allergic reaction Diseases 0.000 title claims description 23
- 101710168479 Granulysin Proteins 0.000 claims abstract description 98
- 102100021186 Granulysin Human genes 0.000 claims abstract description 97
- 230000014509 gene expression Effects 0.000 claims abstract description 52
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 48
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 40
- 239000002207 metabolite Substances 0.000 claims abstract description 32
- 238000000338 in vitro Methods 0.000 claims abstract description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 20
- 229920001184 polypeptide Polymers 0.000 claims abstract description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 18
- 238000006243 chemical reaction Methods 0.000 claims abstract description 12
- 238000012258 culturing Methods 0.000 claims abstract description 11
- 239000012472 biological sample Substances 0.000 claims abstract description 10
- 230000001939 inductive effect Effects 0.000 claims abstract description 9
- 239000000427 antigen Substances 0.000 claims abstract description 8
- 102000036639 antigens Human genes 0.000 claims abstract description 8
- 108091007433 antigens Proteins 0.000 claims abstract description 8
- 230000006044 T cell activation Effects 0.000 claims abstract description 7
- 229960005486 vaccine Drugs 0.000 claims abstract description 7
- 230000000172 allergic effect Effects 0.000 claims abstract description 5
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 5
- 238000001514 detection method Methods 0.000 claims description 33
- 238000002965 ELISA Methods 0.000 claims description 21
- 239000000523 sample Substances 0.000 claims description 20
- 238000012360 testing method Methods 0.000 claims description 20
- 208000019872 Drug Eruptions Diseases 0.000 claims description 16
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims description 14
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims description 14
- 208000032678 Fixed drug eruption Diseases 0.000 claims description 11
- 208000012587 fixed pigmented erythema Diseases 0.000 claims description 11
- 239000013615 primer Substances 0.000 claims description 10
- 206010059284 Epidermal necrosis Diseases 0.000 claims description 9
- 206010015150 Erythema Diseases 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 9
- 231100000321 erythema Toxicity 0.000 claims description 9
- 231100000331 toxic Toxicity 0.000 claims description 9
- 230000002588 toxic effect Effects 0.000 claims description 9
- 238000003556 assay Methods 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108091034117 Oligonucleotide Proteins 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 238000003501 co-culture Methods 0.000 claims description 7
- 230000009885 systemic effect Effects 0.000 claims description 7
- 206010037868 Rash maculo-papular Diseases 0.000 claims description 6
- 210000005259 peripheral blood Anatomy 0.000 claims description 6
- 239000011886 peripheral blood Substances 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 239000002987 primer (paints) Substances 0.000 claims description 5
- 208000012965 maculopapular rash Diseases 0.000 claims description 4
- 239000003155 DNA primer Substances 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000002751 oligonucleotide probe Substances 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 15
- 102000004169 proteins and genes Human genes 0.000 abstract description 10
- 229940126678 chinese medicines Drugs 0.000 abstract description 4
- 230000000977 initiatory effect Effects 0.000 abstract description 4
- 229940126673 western medicines Drugs 0.000 abstract description 4
- 239000000047 product Substances 0.000 description 31
- 108010074328 Interferon-gamma Proteins 0.000 description 17
- 102100037850 Interferon gamma Human genes 0.000 description 16
- 239000001963 growth medium Substances 0.000 description 14
- 230000035945 sensitivity Effects 0.000 description 13
- 206010067484 Adverse reaction Diseases 0.000 description 9
- 230000006838 adverse reaction Effects 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 206010073508 Drug reaction with eosinophilia and systemic symptoms Diseases 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 206010014950 Eosinophilia Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 208000009743 drug hypersensitivity syndrome Diseases 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108010047620 Phytohemagglutinins Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000001885 phytohemagglutinin Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002359 drug metabolite Substances 0.000 description 1
- 208000022143 drug rash with eosinophilia and systemic symptoms Diseases 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000012898 one-sample t-test Methods 0.000 description 1
- HXNFUBHNUDHIGC-UHFFFAOYSA-N oxypurinol Chemical compound O=C1NC(=O)N=C2NNC=C21 HXNFUBHNUDHIGC-UHFFFAOYSA-N 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- -1 vaccine Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
【選択図】図1
Description
グラニュライシン(granulysin):
5’−TCTCTCGTCTGAGCCC−3’、
5’−GCAGCATTGGAAACACT−3’。
5’−ACATCCGCAAAGACCT−3’、
5’−AGGG TGTAACGCAACTA−3’。
Claims (13)
- 生物サンプルからのリンパ球細胞と被疑薬又はその代謝産物とをインビトロで共培養して生成物を形成するステップ1と、
生成物中のグラニュライシンのタンパク質、ポリペプチド又はmRNAの発現レベルを検出して対照値と比較し、グラニュライシンのタンパク質、ポリペプチド又はmRNAの発現レベルが対照値よりも1.2倍以上高かった場合、被疑薬又はその代謝産物が起因薬物であると判定するステップ2と、
を含むことを特徴とする、薬物アレルギー反応の起因薬物を同定する方法。 - ステップ2では、グラニュライシンの発現レベルを検出するために、特異的な捕捉抗体及び検出抗体を用いて生成物中のグラニュライシンのタンパク質又はポリペプチドに対して反応することを特徴とする、請求項1に記載の薬物アレルギー反応の起因薬物を同定する方法。
- ステップ2では、グラニュライシンの発現レベルを検出するために、特異的なオリゴヌクレオチドプライマー又はプローブを用いて生成物中のグラニュライシンのmRNAに対して反応することを特徴とする、請求項1に記載の薬物アレルギー反応の起因薬物を同定する方法。
- リンパ球細胞は、末梢血液からの細胞又は生物個体から単離される体液を含み、より好ましい源は末梢血液であることを特徴とする、請求項1に記載の薬物アレルギー反応の起因薬物を同定する方法。
- 生成物中のグラニュライシン発現レベルを捕捉抗体及び検出抗体により同定する方法は、酵素結合免疫吸着アッセイ又は酵素結合イムノスポットアッセイであることを特徴とする、請求項2に記載の薬物アレルギー反応の起因薬物を同定する方法。
- 薬物アレルギー反応は、スティーブンス・ジョンソン症候群、中毒性表皮壊死症、好酸球増多および全身症状を伴う薬物発疹、斑丘疹性発疹、重症型多形性紅斑及び固定薬疹を含むことを特徴とする、請求項1に記載の薬物アレルギー反応の起因薬物を同定する方法。
- 前記起因薬物は、西洋薬、漢方薬、ワクチン、及びT細胞活性化を誘導可能な抗原分子を含むことを特徴とする、請求項1に記載の薬物アレルギー反応の起因薬物を同定する方法。
- 試験キットと、検出キットとを備える薬物アレルギー反応の起因薬物を同定するための同定キットであって、
前記試験キットは、試薬と、生物サンプルからのリンパ球細胞と、被疑薬又はその代謝産物とをインビトロで共培養して生成物を形成し、
前記検出キットを前記試験キットから形成される生成物と反応して、生成物中のグラニュライシンのタンパク質、ポリペプチド又はmRNAの発現レベルを検出し、グラニュライシンのタンパク質、ポリペプチド又はmRNAの発現レベルが対照値よりも1.2倍以上高かった場合、この被疑薬又はその代謝産物が起因薬物であると判定することを特徴とする、薬物アレルギー反応の起因薬物を同定する同定キット。 - 前記検出キットは、グラニュライシンタンパク質の発現レベルを検出するために、グラニュライシンに対して特異的な捕捉抗体の1種及び検出抗体の1種を含むことを特徴とする、請求項8に記載の同定キット。
- 前記検出キットは、グラニュライシンmRNAの発現レベルを検出するために、グラニュライシンに対して1対の特異的なオリゴヌクレオチドプライマー又はプローブを含むことを特徴とする、請求項8に記載の同定キット。
- 生成物中のグラニュライシン発現レベルを捕捉抗体及び検出抗体により同定する方法は、酵素結合免疫吸着アッセイ又は酵素結合イムノスポットアッセイであることを特徴とする、請求項9に記載の同定キット。
- 薬物アレルギー反応は、スティーブンス・ジョンソン症候群、中毒性表皮壊死症、好酸球増多および全身症状を伴う薬物発疹、斑丘疹性発疹、重症型多形性紅斑及び固定薬疹を含むことを特徴とする、請求項8に記載の同定キット。
- 前記起因薬物は、西洋薬、漢方薬、ワクチン、及びT細胞活性化を誘導可能な抗原分子を含むことを特徴とする、請求項8に記載の同定キット。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2015/093319 WO2017070916A1 (zh) | 2015-10-30 | 2015-10-30 | 鉴定药物过敏反应之致敏药物的方法与鉴定套组 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018537665A true JP2018537665A (ja) | 2018-12-20 |
JP6726278B2 JP6726278B2 (ja) | 2020-07-22 |
Family
ID=58629679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018522116A Expired - Fee Related JP6726278B2 (ja) | 2015-10-30 | 2015-10-30 | 薬物アレルギー反応の起因薬物を同定するための方法及びキット |
Country Status (6)
Country | Link |
---|---|
US (1) | US20180312922A1 (ja) |
JP (1) | JP6726278B2 (ja) |
KR (1) | KR102131543B1 (ja) |
AU (1) | AU2015413017B2 (ja) |
SG (1) | SG11201803579VA (ja) |
WO (1) | WO2017070916A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114740134B (zh) * | 2022-02-25 | 2024-05-14 | 中国检验检疫科学研究院 | 一种鉴别检疫实蝇有效热处理的方法及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006184072A (ja) * | 2004-12-27 | 2006-07-13 | Louis Pasteur Center For Medical Research | 被検物質の免疫賦活能評価方法 |
US20080050382A1 (en) * | 2006-06-23 | 2008-02-28 | Academia Sinica | Granulysin and uses thereof |
JP2010286375A (ja) * | 2009-06-12 | 2010-12-24 | Hokkaido Univ | 重症薬疹易罹患性診断用マーカー、重症薬疹易罹患性の診断方法および重症薬疹易罹患性診断用キット |
CN102747130A (zh) * | 2012-07-03 | 2012-10-24 | 南京中医药大学 | 一种中药注射液致敏性的检测评价方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013370009B2 (en) * | 2012-12-31 | 2016-11-17 | Academia Sinica | Anti-granulysin antibodies and methods of use thereof |
-
2015
- 2015-10-30 SG SG11201803579VA patent/SG11201803579VA/en unknown
- 2015-10-30 KR KR1020187014692A patent/KR102131543B1/ko active IP Right Grant
- 2015-10-30 AU AU2015413017A patent/AU2015413017B2/en not_active Ceased
- 2015-10-30 JP JP2018522116A patent/JP6726278B2/ja not_active Expired - Fee Related
- 2015-10-30 WO PCT/CN2015/093319 patent/WO2017070916A1/zh active Application Filing
- 2015-10-30 US US15/771,891 patent/US20180312922A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006184072A (ja) * | 2004-12-27 | 2006-07-13 | Louis Pasteur Center For Medical Research | 被検物質の免疫賦活能評価方法 |
US20080050382A1 (en) * | 2006-06-23 | 2008-02-28 | Academia Sinica | Granulysin and uses thereof |
JP2010286375A (ja) * | 2009-06-12 | 2010-12-24 | Hokkaido Univ | 重症薬疹易罹患性診断用マーカー、重症薬疹易罹患性の診断方法および重症薬疹易罹患性診断用キット |
CN102747130A (zh) * | 2012-07-03 | 2012-10-24 | 南京中医药大学 | 一种中药注射液致敏性的检测评价方法 |
Non-Patent Citations (1)
Title |
---|
CHUNG WH、他7名: "Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurino", J INVEST DERMATOL., vol. 135, no. 9, JPN6019014822, September 2015 (2015-09-01), pages 2237 - 2248, XP055378732, ISSN: 0004158317, DOI: 10.1038/jid.2015.165 * |
Also Published As
Publication number | Publication date |
---|---|
US20180312922A1 (en) | 2018-11-01 |
AU2015413017B2 (en) | 2019-09-19 |
KR20180092942A (ko) | 2018-08-20 |
SG11201803579VA (en) | 2018-05-30 |
JP6726278B2 (ja) | 2020-07-22 |
KR102131543B1 (ko) | 2020-07-09 |
WO2017070916A1 (zh) | 2017-05-04 |
AU2015413017A1 (en) | 2018-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Brunner et al. | Distinct transcriptomic profiles of early-onset atopic dermatitis in blood and skin of pediatric patients | |
JP6337020B2 (ja) | 急性呼吸促迫症候群(ards)関連バイオマーカーを測定する方法、患者におけるardsの進行および治療をモニターする方法 | |
US20210389308A1 (en) | Detecting adaptive immunity to coronavirus | |
CN103930565B (zh) | 用于痤疮的新th17分化标志物及其用途 | |
Muntyanu et al. | Differential gene and protein expression of chemokines and cytokines in synovial fluid of patients with arthritis | |
Raju et al. | Gene expression profiles of bronchoalveolar cells in pulmonary TB | |
Singh et al. | Inflammatory chemokines and their receptors in human visceral leishmaniasis: gene expression profile in peripheral blood, splenic cellular sources and their impact on trafficking of inflammatory cells | |
Veroni et al. | Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis | |
Huang et al. | Cytokine antibody arrays in biomarker discovery and validation | |
TW201918560A (zh) | 一種用於檢測、預測和監測癌症的循環rna | |
JP6726278B2 (ja) | 薬物アレルギー反応の起因薬物を同定するための方法及びキット | |
WO2017026691A1 (ko) | 비만의 진단용 조성물 및 이의 용도 | |
US20230203602A1 (en) | Methods for detecting respiratory viral infection | |
JP6366503B2 (ja) | ざ瘡についての新規th17分化マーカーおよびその使用 | |
ES2805056T3 (es) | Biomarcadores de TB | |
CN106755291B (zh) | 用于筛查克林霉素所致皮肤药物不良反应的人类白细胞抗原基因检测试剂盒 | |
US20230212699A1 (en) | Methods to detect and treat sars-cov-2 (covid19) infection | |
TWI606237B (zh) | Methods and identification kits for the identification of sensitized drugs for drug allergy | |
US20230014092A1 (en) | Materials and methods for monitoring inflammation | |
Dutta et al. | Immune response during influenza virus infection among the population of Assam, Northeast India | |
US20220056528A1 (en) | Method of detecting infection with pathogens causing tuberculosis | |
WO2006086573A2 (en) | Diagnostic assay for orientia tsutsugamushi by detection of responsive gene expression | |
US20230003719A1 (en) | Materials and methods for inflammatory molecular markers | |
US20240026450A1 (en) | Method of detecting infection with pathogens causing tuberculosis | |
TWI695889B (zh) | 評估抗生素磺胺甲噁唑及/或甲氧苄啶引發藥物過敏反應風險的方法、其檢測試劑及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180517 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180627 |
|
A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A80 Effective date: 20180720 Free format text: JAPANESE INTERMEDIATE CODE: A801 Effective date: 20180720 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190423 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190426 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190723 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190725 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200225 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20200514 |
|
TRDD | Decision of grant or rejection written | ||
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200514 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200623 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200626 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6726278 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |